Stelara® (Ustekinumab)

DRUG2 trials

Sponsors

Bioeq GmbH, Samsung Bioepis Co., Ltd.

Conditions

Moderate to Severe Plaque PsoriasisPlaque PsoriasisPsoriasis

Phase 3

A Double-blind Study to Compare the Efficacy, Safety, and Immunogenicity of the Proposed Biosimilar Ustekinumab FYB202 to Stelara® in Patients With Moderate-to-Severe Plaque Psoriasis

CompletedNCT04595409

Bioeq GmbHPlaque Psoriasis

Start: 2020-11-09End: 2022-03-21Updated: 2023-02-16

A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to Stelara® in Subject With Moderate to Severe Plaque Psoriasis

CompletedNCT04967508

Samsung Bioepis Co., Ltd.Moderate to Severe Plaque Psoriasis, Psoriasis

Start: 2021-07-06End: 2022-11-25Updated: 2025-05-25

Related Papers

A Randomised, Double-Blind Trial to Compare the Efficacy, Safety, and Immunogenicity of the Biosimilar Ustekinumab FYB202 with Reference Ustekinumab in Patients with Moderate-to-Severe Plaque Psoriasis

Advances in Therapy2025-03-061 citations